Small Study Offers Hope for Lung Cancer Patients

MAY 01, 2004
Susan Farley

In a study of patients with non?small-cell lung cancer, 3 of the 43 participants injected with the vaccine GVAX had no recurrence of lung cancer for more than 3 years. Researchers note that the trial was very small, and the vaccine is years away from reaching the market, if ever. The oncologist who led the study, John Nemunaitis, MD, of Baylor University Medical Center, said, "The results are very promising for patients with non?small-cell lung cancer, which is frequently resistant to chemotherapy." He added that this is the first study to show complete and long-lasting regression of lung cancer by stimulating the immune system to attack cancer cells. This type of lung cancer is the most common, killing more than 150,000 people each year.



SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.